Sign In
Buy RFL
$1.35
-0.0200 (-1.46%)
At Close: Jun 03, 2026
Terra Clean Energy Corp. Enters into Definitive Agreements to Acquire Uranium Claims on the San Rafael Swell, Utah, United States
08:30am, Wednesday, 24'th Sep 2025
Vancouver B.C. - TheNewswire - September 24, 2025 – TERRA CLEAN ENERGY CORP. (“ Terra ” or the “ Company ”) (CSE: TCEC, OTCQB: TCEFF , FSE: C 9O0) , is pleased to announce that, further to i
Vancouver B.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF , FSE: 9O0), is pleased to announce terms to acquire up to a 100
Vancouver B.C. – TheNewswire - September 16, 2025 – TERRA CLEAN ENERGY CORP. (“ Terra ” or the “ Company ”) (CSE: TCEC, OTCQB: TCEFF, FSE: 9O0 , is pleased to announce terms to acquire up
First data on treatment of NPC1 with Trappsol ® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients 1 showed stabiliza
TI Chief Financial Officer Rafael Lizardi to speak at Citi investor conference
02:13pm, Wednesday, 20'th Aug 2025
DALLAS , Aug. 20, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Citi 2025 Global TMT Confer
Rafael Sanchez Joins Bloomin' Brands as Chief Information Officer
04:05pm, Tuesday, 24'th Jun 2025
TAMPA, Fla.--(BUSINESS WIRE)--Bloomin' Brands, Inc. (Nasdaq: BLMN) announced the appointment of Rafael Sanchez as Senior Vice President & Chief Information Officer. Sanchez joins the company from Davi
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
07:00am, Wednesday, 11'th Jun 2025
NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal ye
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
04:01pm, Wednesday, 04'th Jun 2025
NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Righ
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
04:01pm, Tuesday, 20'th May 2025
NEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today provided an update to the subscription rights related to its Public Warrants in connection
TI Chief Financial Officer Rafael Lizardi to speak at Bank of America investor conference
01:10pm, Monday, 19'th May 2025
DALLAS , May 19, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Bank of America 2025 Global
NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights o
NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is desi
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results f
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
06:50am, Wednesday, 26'th Mar 2025
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results fr
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
05:50pm, Thursday, 13'th Mar 2025
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol ®
